A PERFORMANCE NOT TO BE MISSED...

Dear Healthcare Professional | July 2020

It gives Adcock Ingram great pleasure to inform you that South Africa's first infliximab biosimilar, REMSIMA®, is now available for use in rheumatology, gastroenterology and dermatology [1,2,3]

WITH ALMOST A DECADE OF EXPERIENCE[2]

with exposure reaching 24,000 patient-years treated worldwide,[1] REMSIMA® demonstrated:

- Direct and comparable long term efficacy, immunogenicity, safety and PK-PD versus originator in patients with RA inadequately responding to MTX [4,5]
- Direct and comparable long term efficacy versus originator in patients with AS [6,7]
- Effective in the induction and maintenance of clinical remission in patients with IBD [2]
- REMSIMA® is generally well tolerated, with a similar safety profile to that of reference infliximab [2]

REMSIMA® is approved for the same indications as reference infliximab: RA, AS, PsA, psoriasis, Crohn's disease and ulcerative colitis [2]

Product	Reg. number	Schedule	Bar Code[8]	Nappi code	Price (excl. VAT)	Price (incl. VAT)
Remsima® 100mg	52/30.1/0309	S4	6004406006493	3001518001	R 3684.78	R 4237.50

Our team is dedicated to providing you and your practice with not only a professional service, but access to the latest clinical and therapeutic information. You are most welcome to contact Adcock Ingram to facilitate an enquiry. We look forward to being of service to you, your practice and your patients.

Yours sincerely,

Chanel Chengan
Marketing and Sales Manager: Biologics
Customer Care Line 0860 ADCOCK I 232625
Email: Info.Biosimilars@adcock.com

Remsima® Infliximab
A biological within reach

References: 1. Braun J, Kudrin A. Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health. *Biologicals* 2016;**44**:257-266. **2.** Blair HA, Deeks ED. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases. *BioDrugs* 2016;**30**:469–480. **3.** IMS (MAT) data: May 2020. **4.** Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranauskaite A, *et al.* A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. *Arthritis Res Ther.* 2016;**18**:82. doi: 10.1186/s13075-016-0981-6. **5.** Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, *et al.* Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. *Ann Rheum Dis.* 2017;**76**:355–363. **6.** Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, *et al.* Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. *Arthritis Res Ther.* 2016;**18**:25. doi: 10.1186/s13075-016-0930-4. **7.** Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-Ureña S, *et al.* Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. *Ann Rheum Dis* 2017;**76**:346–354. **8.** Adcock Ingram data on file. 23 March 2020.

HEALTHCARE CELLTRION

adcock ingram